drugset

drugset / Trial / NCT07266480

Clinical Study of Adbelimumab in the Adjuvant Treatment of Esophageal Squamous Cell Carcinoma.

NCT07266480 ↗

Phase 2 Recruiting 142 enrolled Hebei Medical University Fourth Hospital

RandomizedParallel-groupOpen-labelTreatment

Summary

Evaluating the efficacy and safety of adebrelizumab for the adjuvant treatment of esophageal squamous cell cancer.

Timeline

Start: 2025-09-01
Primary completion: 2027-09-01
Completion: 2030-09-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Adebrelizumab	Unknown	1200 mg	Intravenous

Indications